Some chemotherapy and antibody drugs damage the heart. Checking heart function before and during treatment and starting protective drugs early for those at risk could prevent much of that damage.
Anthracyclines, HER2-targeted therapy, and some kinase inhibitors cause cardiac dysfunction that is often detected late. Guidelines (ESC 2022 cardio-oncology) recommend baseline risk assessment, biomarker and strain-imaging surveillance, and cardioprotective therapy for high-risk patients, but implementation is inconsistent and cardio-oncology clinics are rare outside academic centres. A pathway with automatic risk scoring at prescription, scheduled surveillance, and protocolised initiation of protective therapy would standardise this.
Shares Cardio-oncology, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Trastuzumab, Survivorship and late effects are neglected.
Shares Cardio-oncology, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Survivorship and late effects are neglected.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Toxicity and quality of life are undervalued.
Shares Cardio-oncology, Trastuzumab, Survivorship and late effects are neglected, HER2-positive breast cancer.
Shares Cardio-oncology, Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab, HER2-positive breast cancer, Diffuse large B-cell lymphoma.
Shares Cardio-oncology, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Survivorship and late effects are neglected.